Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2021 0 · FY2022 0 · FY2023 0
Georgian pharmacy/pharmaceutical distribution company.
Subsidiary of Epa (90.0%)
| Line item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | CAGR |
|---|---|---|---|---|---|---|---|---|
| Net Cash from Operating Activities | 1,092 | 69 | 2,716 | 3,585 | 5,996 | 3,175 | 6,297 | +33.9% |
| Net Cash used in Investing Activities | 0 | 242 | 114 | 1,294 | 1,417 | 1,549 | 3,218 | +67.8% |
| Free Cash Flow (OCF − Capex proxy) | 1,092 | 311 | 2,830 | 4,879 | 4,578 | 4,724 | 3,079 | +18.9% |
| Net Cash from Financing Activities | 0 | 166 | 4,683 | 4,117 | 5,558 | 4,683 | 3,412 | +83.1% |
| Net Change in Cash (before FX) | 1,092 | 145 | 1,853 | 762 | 980 | 41 | 6,491 | +34.6% |
| Effect of FX on Cash | 0 | 3 | 27 | 61 | 13 | 25 | 264 | nmf |
| Net Change in Cash (incl. FX) | 1,092 | 142 | 1,826 | 823 | 993 | 15 | 6,227 | +33.7% |
| Cash at Beginning of Year | 0 | 485 | 343 | 2,169 | 1,346 | 353 | 338 | -7.0% |
| Cash at End of Year | 0 | 343 | 2,169 | 1,346 | 353 | 338 | 6,565 | +80.5% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →